Trial Information

Summary: A Phase I Study of MP470 in Combination with Standard of Care Chemotherapy Regimens

The purpose of this study is to determine the safety and tolerability of MP 470 when administered in combination with standard of care chemotherapy regimens in patients with advanced solid tumors. The combinations are:

• MP 470 with Carboplatin and Etoposide
• MP 470 with Docetaxol
• MP 470 with Taxol and Carboplatin
• MP 470 with Topotecan
• MP 470 with Erlotinib

The study will assess the effects of the drug on patients and their cancers and study the pharmacokinetics of MP 470 when used in these combinations. Pharmacokinetics (PKs) is a way to determine the level of a drug in the patient's blood and to study how the body processes the drug by looking at how the drug is absorbed, disseminated, metabolized and eliminated. This is done by frequent blood draws on key days during the first four weeks of treatment.

MP 470 is a targeted therapy and an oral, multi-targeted tyrosine kinase inhibitor. It has inhibitory activity against c-met, c-ret, mutant c-kit and á-PDGFR. MP470 is not approved by the FDA and is considered investigational in this study. All of the other drugs with which it is combined are FDA-approved for use in various cancers.

Patient Inclusion Criteria:

• Measurable disease
• LVEF >50%

Patient Exclusion Criteria:

• Left bundle branch block
• QTc Interval > 450
• Hypokalemia

If you would like to learn more about participating in this study, please send an e-mail message using the form below.